Original Article - Urological Oncology

Investig Clin Urol 2018;59:91-97. https://doi.org/10.4111/icu.2018.59.2.91 pISSN 2466-0493 • eISSN 2466-054X





What do patients with urothelial cancer know about the association of their tumor disease with smoking habits? Results of a German survey study

Matthias May¹, Hans-Martin Fritsche², Christian Gilfrich¹, Mirja Dombrowski², Odilo Maurer¹, Philipp Spachmann², Manju Ganesh Kumar², Marc Bjurlin³, Maximilian Burger², Sabine Brookman-May^{4,5}

¹Department of Urology, St. Elisabeth Hospital Straubing, Straubing, ²Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany, ³Department of Urology, New York University Langone Hospital, New York University School of Medicine, New York, NY, USA, ⁴Department of Urology, Ludwig-Maximilians University (LMU), Munich, Germany, ⁵Department of Urology, Janssen Pharma Research and Development, Los Angeles, CA, USA

Purpose: Smoking represents a primary risk factor for the development of urothelial carcinoma (UC) and a relevant factor impacting UC-specific prognosis. Data on the accordant knowledge of UC-patients in this regard and the significance of physicians in the education of UC-patients is limited.

Materials and Methods: Eighty-eight UC-patients were enrolled in a 23-items-survey-study aimed to analyse patient knowledge and awareness of their tumor disease with smoking along with physician smoking cessation counselling.

Results: The median age of the study patients was 69 years; 26.1% (n=23), 46.6% (n=41), and 27.3% (n=24), respectively, were non-smokers, previous, and active smokers. Exactly 50% of active smokers reported a previous communication with a physician about the association of smoking and their tumor disease; however, only 25.0% were aware of smoking as main risk factor for UC development. Merely 33% of the active smokers had been prompted directly by their physicians to quit smoking. About 42% of active smokers had received the information that maintaining smoking could result in a tumor-specific impairment of their prognosis. Closely 29% of active and about 5% of previous smokers (during the time-period of active smoking) had been offered support from physicians for smoking cessation. No association was found between smoking anamnesis (p=0.574) and pack-years (p=0.912), respectively, and tumor stage of UC.

Conclusions: The results of this study suggest that the medical conversation of physicians with UC-patients about the adverse significance of smoking is limited. Implementation of structured educational programs for smoking cessation may be an opportunity to further enhance comprehensive cancer care.

Keywords: Cigarette smoking; Health facility planning; Neoplasm staging; Surveys and questionnaires; Urinary bladder neoplasms

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 14 November, 2017 • Accepted: 16 January, 2018 Corresponding Author: Matthias May Department of Urology, St. Elisabeth Hospital Straubing, St. Elisabeth Str. 23, 94315 Straubing, Germany TEL: +49-9421-710-1700, FAX: +49-9421-710-1717, E-mail: matthias.may@klinikum-straubing.de ORCID: http://orcid.org/0000-0003-3896-0405

www.icurology.org

INTRODUCTION

Based on 2013 estimations of the World Health Organization, about one billion people worldwide were active smokers and around six million people died from diseases caused by smoking, including mainly cardiovascular and pulmonary diseases as well as cancer [1]. Epidemiological studies on upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB) have identified several etiological risk factors, with cigarette smoking and exposure to certain occupational agents being of highest importance [2-4]. Out of the more than 60 carcinogens and free reactive oxygen radicals, the main relevant metabolites responsible for urothelial carcinoma (UC) development are not reliably identified yet; however, it is proven that smoking impairs cellular DNA repair mechanisms, which subsequently diminishes the body's defence mechanisms (host response) against carcinogens [4,5].

In 2013, 382,700 new cases of UCB were diagnosed worldwide and they were 143,000 associated deaths [1,6]. In half of UCB-patients smoking is the most relevant risk factor; while studies have shown that smoking cessation in UCB-patients significantly reduces the risk for recurrence [7-10]. Based on the results of a recent meta-analysis of 83 studies, the relative risk for developing UCB was 258 (95% confidence interval [CI], 2.37 to 2.80) in all smokers, with active smokers having a relative risk of 3.47 (95% CI, 3.07 to 3.91) while the relative risk of former smokers was 2.04 (95% CI, 1.85 to 2.25) [1]. In addition, cancer-specific mortality was higher in smokers (active and previous smokers combined) by 47% (95% CI, 2.4% to 75%) [1].

Finally, there is an abundance of evidence that physicians should provide smoking prevention and cessation counselling in a prophylactic manner for promotion and maintenance of personal health. The time of UC diagnosis has been shown to be a "teachable moment," highlighting an opportunity for urologists and oncologists to recommend rigorous smoking cessation to enhance the individual tumor-specific prognosis. To date, a paucity of data exists on the knowledge of UCpatients regarding the association of their tumor disease with smoking habits. Furthermore, limited studies have investigated which communication between doctors and patients on this critical point is undertaken in clinical routine and which resources and aids for smoking cessation are offered by physicians (and mainly urologists) to UCpatients who are active smokers. In a survey conducted at the Johns Hopkins Hospital in Baltimore by Guzzo et al. [11] on 71 UCB-patients only 84.5% were aware of smoking as a risk factor for UCB development and 59% of active and previous smokers were advised by their urologists to quit smoking or not to restart again. Studies on this topic conducted in Europe are yet pending.

The aim of the present bicentric survey study was to analyze knowledge and awareness level of UC-patients concerning the association of their tumor disease with smoking. Furthermore, we aimed to evaluate the association of smoking habits and tumor stage. Based on the analysis of available services for smoking cessation and the time volume of accordant informative conversations, also the status quo concerning current implementation of elementary and selffinancing conversations of physicians with their patients will be displayed.

MATERIALS AND METHODS

1. Study conduction

A survey comprising 23 items was developed with the aim of assessing knowledge and awareness level of in-house patients with a histologically confirmed genitourinary malignancy (UTUC, UCB, renal, prostate, and testicular cancer) on the association of their tumor disease (and other urological tumors) and cigarette smoking (concerning tumor development and prognosis). Selective questions were integrated to assess 1) the manner and the extent of medical informative conversations conducted in this regard and 2) the resources provided to patients for smoking interruption or cessation. Previous smokers were asked for their individual reasons that had led them to guit smoking, and current smokers were queried for their concrete further intention regarding cigarette consumption. Prior to study initiation the survey was validated on 25 patients with uro-oncological diseases to confirm comprehensibility and clarity of questions. Study inclusion criteria were histologic confirmation of a urologic malignancy, the capability of informed consent, and an age of at least 18 years. The study title was defined as "Knowledge of tumor patients regarding the Risk Association of smoking habits and Urological Tumors" (KRAUT study); ethical committee approval of the State Chamber of Medicine in Brandenburg was obtained (BLAEK-EK no. 13012). Written informed consent was obtained from all patients before enrolment. The study was conducted between September 1st 2013 and December 31st 2014 in two urological departments (Caritas St. Josef Medical Center, University of Regensburg; St. Elisabeth Hospital Straubing; Academic Teaching Hospital of TU Munich University) [12,13]. In addition to the 23 items of the survey, demographic, clinical, and oncological information was obtained from all enrolled 258 patients (UC, n=88; renal

cancer, n=34; prostate cancer, n=124; testicular cancer, n=12).

2. Study group and study criteria

The study group comprised 88 patients with histologically confirmed UC (UCB, n=85; UTUC, n=3), who underwent inhouse treatment in two urological departments (Straubing, n=42; Regensburg, n=46). During the assessment period 256 (76+180) UC-patients (coded as C65-67) were treated with an in-house duration of >1 day, so that overall 34.4% of possible patients could be included. They study survey is shown in the Supplementary material. Patient related criteria included age, gender, body mass index (BMI), and tumor manifestation (within three months since diagnosis versus tumor recurrence). Furthermore, clinical-pathological tumor stage was assessed in a dichotomized manner (<c/pT2, c/pN0, c/pM0 vs. muscle-invasive and/or metastasized tumor stages).

3. Statistical analysis

Continuous variables are displayed with medians and interquartile ranges (IQR). To analyze differences in the distribution of continuous parameters between non-smokers and smokers (summarized as active and previous smokers), the Kruskal-Wallis-H Test was applied. The distribution of categorical variables in different groups was compared by chi-square test. If reasonable, descriptive results of nominal scaled items were displayed in summary. Two multivariate logistic regression models (MLRM) were built to assess the independent impact of smoking as dependent dichotomized variables on tumor stage with one model adjusted for the smoking status variable and the second model including the number of pack-years.

The preferable sample size to achieve a statistical

power of 0.8 to 0.85 for this study was neither reached a priori nor post-hoc, as no information was available on the putative effect size for the impact of smoking on the binary categorized tumor stage (see above). This information would have potentially been extractable for cancer-specific mortality analyses from recent meta-analyses; however, for the advised surrogacy analyses of the present study (comparison of tumor stages) this information was not provable [1,9].

For data analysis IBM SPSS Statistics ver. 24.0 (IBM Co, Armonk, NY, USA) was applied. The p-values provided are two-sided with a level of significance defined as p<0.05 for all tests conducted.

RESULTS

Eighty-eight UC-patients (85 and 3 with UCB and UTUC, respectively) were enrolled in the study, of which 23 (26.1%), 41 (46.6%), and 24 (27.3%), respectively, were nonsmokers, previous smokers, and active smokers. Descriptive patient characteristics and comparison between non-smokers and smokers are displayed in Table 1. The median age of the study group was 69 years (IQR, 61 to 73.8 years) with no significant difference between non-smokers and (active as well as previous) smokers (p=0.102). The median age of active and previous smokers was significantly different (64 years vs. 70 years, p=0.002), while there was no significant difference in the median number of pack-years between both groups (29.3 vs. 29.2, p=0.946). Forty-nine patients (55.7%) had a primary UC at the time of study conduction (initial or subsequent treatment within three months of diagnosis), 18 patients (20.5%) presented with muscle invasive and/or metastatic disease.

Study criteria	Study group (n=88)	Non-smokers (n=23)	Smokers (n=65)	p-value
Patient age (y)	69 (61–73.8)	72 (61–77)	67 (60.5–73)	0.102
Male gender	71 (80.7)	20 (87.0)	51 (78.5)	0.542
Body mass index (kg/m²)	26.7 (24.7–30)	26.4 (24.1–30)	26.8 (24.8-30.2)	0.683
Organ distribution of UC				0.564
Renal pelvis	3 (3.4)	0 (0.0)	3 (4.6)	
Urinary bladder	85 (96.6)	23 (100.0)	62 (95.4)	
Disease status				0.808
Primary (≤3 months sD)	49 (55.7)	12 (52.2)	37 (56.9)	
Recurrent disease and/or >3 months sD	39 (44.3)	11 (47.8)	28 (43.1)	
Tumor stage				0.772
<c pt2n0m0<="" td=""><td>70 (79.5)</td><td>19 (82.6)</td><td>51 (78.5)</td><td></td></c>	70 (79.5)	19 (82.6)	51 (78.5)	
≥c/pT2 and/or metastatic stage	18 (20.5)	4 (17.4)	14 (21.5)	

Table 1. Distribution of clinical and oncological criteria in 88 patients with UC of the renal pelvis or bladder, distributed in non-smokers and smokers (active and previous smokers)

Values are presented as median (range) or number (%).

UC, urothelial carcinoma; sD, since primary diagnosis.

May et al

ICUROLOGY

Exactly 64.9% of patients who responded to these questions (50/77) considered it possible that cigarette consumption could generally impact UCB development. Forty of 67 patients (59.7%) considered it as conceivable or proven that cigarette consumption impacts UCB prognosis. In comparison, 100% of patients who responded to both questions considered the impact of smoking on the development and/or prognosis of bronchial carcinoma as probable or proven. There was a significant agreement in the judgement of those patients, who estimated the impact of smoking on UC development and prognosis as possible or proven (p<0.001).

Exactly 32.3% of smokers (21/65) confirmed to have altered their cigarette consumption due to their tumor disease. Ten of these 21 patients had quit smoking after UC diagnosis, furthermore 11 had reduced consumption. Additionally, 31 patients had stopped smoking for various reasons unrelated to their tumor disease. Fifteen of 24 active smokers (62.5%) confirmed that they would have stopped smoking immediately if they had known about a possible association with UC development and prognosis. Only six of 24 active smokers (25.0%) and 10 of 41 previous smokers (24.4%) considered smoking the main cause of UC development.

Eight of 24 active smokers (33.3%) had been directly advised by their treating physicians to quit smoking due to their tumor disease and of 41 previous smokers, 12 patients (29.3%) had received a clear recommendation by their physician(s) to stop smoking due to their tumor disease or to not restart smoking again. Ten of 24 active smokers (41.7%), 17 of 41 previous smokers (41.5%) and 5 of 23 nonsmokers (21.7%) had an accordant informative conversation with their urologist concerning the association of cigarette consumption and UC prognosis (further 8.3%, 7.3% and 4.3%, respectively, received this information exclusively by physicians from other medical specialties). On the other hand, of 24 active and 41 previous smokers 7 (29.2%) and 13 (31.7%) patients indicated that they don't require an informative conversation with physicians or don't consider such conversation as necessary. Seven active smokers (29.2%) and 2 previous smokers (4.9%) had been offered services for smoking cessation. Nine patients only of the entire study group (10.2%) indicated that the cumulative time used for accordant informative conversations on the association of cigarette smoking with urological tumor diseases comprised 10 minutes or more.

Exactly 17.4% (4/23), 24.4% (10/41), and 16.7% (4/24) of nonsmokers, previous smokers, and active smokers, respectively, presented with muscle-invasive and/or metastatic disease (group comparison, p=0.772). Both smoking anamnesis (odds ratio [OR], 1.46; p=0.574) and cumulative dose/pack-years (OR, 1.00; p=0.912) didn't have an independent impact on tumor stage (Table 2). BMI had a significant impact on this

Table 2. Multivariate logistic regression model to evaluate the independent impact of different criteria on the presences of muscle-invasive and/ or metastatic disease

Study criteria	Model 1	p-value	Model 2	p-value
Patient age (y)	1.04 (0.97–1.11)	0.305	1.03 (0.97–1.11)	0.336
Female gender (ref.: male gender)	1.71 (0.43–6.81)	0.444	1.75 (0.44–6.99)	0.429
Body mass index (kg/m²)	0.82 (0.71–0.96)	0.012	0.82 (0.71–0.96)	0.012
Smoker (ref.: non-smoker)	1.46 (0.39–5.44)	0.574	-	
Pack-years (y)	-		1.00 (0.98–1.03)	0.912

Values are presented as odds ratio (95% confidence interval).

Model 1 with inclusion of smoking status (active and previous smokers vs. non-smokers), Model 2 with inclusion of pack-years.




Fig. 1. Results of multivariate regression analysis for the impact of smoking status (active or previous smokers vs. non-smoker) on tumor stage (presence of muscle-invasive and/or metastatic urothelial carcinoma). OR, odds ratio; CI, confidence interval; BMI, body mass index; ref., reference; NS, non-smoker.

endpoint with every increase in BMI per kg/m² reducing the possibility of muscle-invasion and/or metastatic tumor stage by 18% (95% CI, 4% to 29%; p=0.012) (Table 2, Fig. 1).

DISCUSSION

Health care providers are urged to advise their patient population about the significant impact of smoking on cancer development and the associated increase of cardiovascular and pulmonary morbidity and mortality. Programs and initiatives to increase the awareness in this regard should aim to counsel non-smokers to maintain their abstinence and to recommend smokers to quit smoking. Besides impairment of different organ functions (and subsequently potentially also the individual capability for surgery and anaesthesia), smoking contributes to UC, renal, and penile cancer development as well as impacts prognosis of UC and prostate cancer patients [14,15]. For UC (especially UCB) the evidence is consistent and reliable: smoking represents the main risk factor for cancer development and is additionally associated with an impairment of the cancer-specific prognosis [1-10]. Furthermore, the association between smoking duration and intensity with erectile dysfunction is clearly proven [16]. Taken together, these smoking related genitourinary diseases place the urologist in a unique position to provide smoking cessation guidance.

Which conclusions should urologists draw by the abovementioned insights and the results of our survey? About 74% of study participants with histologically confirmed UC were active or previous smokers; for both groups of smokers about 30 pack-years were calculated on average with no significant difference between both groups. Although 50% of patients who were active smokers at the time of diagnosis had a conversation with their physician(s) about the correlation of their tumor disease with smoking, only 25% were aware of smoking as main risk factor of UC development. One third of active smokers only were directly asked by their physicians to quit smoking and 42% of patients belonging to this group were informed that maintenance of smoking could result in a tumor-specific impairment of their prognosis. 29% of active smokers and 5% of previous smokers only were offered support for smoking cessation by their physicians during their active smoking period. Also, only 10% of the entire study group had informative and educational conversations about the potential negative impact of smoking of cumulatively at least 10 minutes. Based on the results of this survey, it appears that urologists inadequately communicate (as it concerns time and content) with UCpatients about the adverse impact of smoking. Further studies have confirmed this observation and indicate a need for optimization in this regard on a worldwide level [11,17-21]. In a study by Bjurlin et al. [18] on 535 in-house urological patients with different diseases 25% of patients considered smoking as relevant for UCB development. The study results published by Westhoff et al. [19] on 1,735 long-term survivors with UCB recorded in the Netherlands Cancer Registry between 2007 and 2012 even showed that only 10% considered smoking as causative for UCB development. In a 2013 national survey of urologists, Bjurlin et al. [22] indicated that urologists have the responsibility to counsel their patients by structured education and provision of specific support for smoking cessation to strictly guit smoking. How this "teachable moment" at the time of cancer diagnosis could be used to motivate patients to completely change their lifestyle (including smoking reduction or cessation) has been addressed by a structured program introduced by Lee et al. [23]. In this regard, urologists should also be aware of their function as primary contact for UC-patients and should aim to extend their core competence in diagnostics and treatment of this disease also to aspects of lifestyle changes impacting the course of disease.

Based on the results of our study we could not confirm an association between cigarette smoking and the presence of advanced tumor stages. 17.4% and 21.5%, respectively, of non-smokers and (active and previous) smokers had a tumor stage >c/pT1N0M0 (p=0.772). Based on two multivariable models neither smoking status (smoker vs. non-smoker) nor the cumulative smoking dose (based on pack-years) had an independent impact on tumor stage. Also, when this category was adapted (e.g., >c/pTaN0M0), smoking status and cumulative dose didn't significantly impact this endpoint (results not shown). In contrast, larger studies with better definition of advanced UC stages could show an association with smoking and more aggressive tumors [24,25]. Interestingly, in the present study, BMI was the only criterion significantly impacting tumor stage, while every increase in BMI per kg/m² reduced the risk of a muscleinvasive and/or metastasized tumor stage by 18% (p=0.012). The international evidence is inconsistent in this regard, however, the association between a higher BMI and less advanced tumor stages has been described by other work groups as well [26,27].

Several limitations concerning the interpretation of our study need to be considered. In addition to the overall limited number of patients participating in this survey, only 34.4% of possible UC-patients could be included. This is remarkable, as this selection bias (participants vs. responders) could potentially also impact results; furthermore, potentially

May et al

significant differences could fail due to limited statistical power (see also MATERIALS AND METHODS section). Since the KRAUT study was developed for urological cancer patients in general, but not specifically for UCpatients, clinical and oncological criteria gathered in the survey population represent a compromise to cover different urological tumors; desired UC specific criteria (treatment modalities) and general criteria (occupational exposure, educational status, assignment to different referring medical specialties) were not collated. Due to the lack of validated questions in this specific setting, the items of this study were self-designed. However, prior to study start, all survey questions were validated in structured interviews with 25 uro-oncological patients in one hospital (St. Elisabeth Hospital Straubing, Germany). Furthermore, this study was conducted as a survey, hence, honesty of patients concerning their smoking habits is desired, but not a precondition which can be postulated. In addition, not all items were responded by all patients (whereas all questionnaires were controlled for plausibility by both data responsible persons [MD, OM] together. Based on the evaluated questions, we could not generate findings about secondary smoking exposure, which could impact study results (especially in cases of long-term exposition). Patients included in the KRAUT study were not further followed for their oncological course.

CONCLUSIONS

The knowledge of UC-patients concerning the general association of their tumor disease with smoking seems to be limited. Comparable to other tobacco associated cancers, the time of UC diagnosis may allow physicians to use this time-point as a "teachable moment" in order to educate patients in a structured manner and to offer active smokers sufficient support for smoking cessation. Urologists remain in a unique position and should actively counsel patients concerning possible lifestyle changes, ultimately strengthening their role as primary partners of UC-patients in the comprehensive therapeutic management of UC.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

SUPPLEMENTARY MATERIAL

Scan this QR code to see the supplementary material, or visit https://www.icurology.org/src/sm/icurology-59-91-s001.pdf.

ICUROLOGY



REFERENCES

- Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol 2016;70:458-66.
- 2. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306:737-45.
- 3. McLaughlin JK, Silverman DT, Hsing AW, Ross RK, Schoenberg JB, Yu MC, et al. Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res 1992;52:254-7.
- Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol 2017;24:730-4.
- Rouissi K, Ouerhani S, Hamrita B, Bougatef K, Marrakchi R, Cherif M, et al. Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia. Pathol Oncol Res 2011;17:879-86.
- Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality. Eur Urol 2014;66:59-73.
- 7. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-41.
- Chen CH, Shun CT, Huang KH, Huang CY, Tsai YC, Yu HJ, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int 2007;100:281-6; discussion 286.
- Hou L, Hong X, Dai M, Chen P, Zhao H, Wei Q, et al. Association of smoking status with prognosis in bladder cancer: a meta-analysis. Oncotarget 2017;8:1278-89.
- Strope SA, Montie JE. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol 2008;180:31-7; discussion 37.
- Guzzo TJ, Hockenberry MS, Mucksavage P, Bivalacqua TJ, Schoenberg MP. Smoking knowledge assessment and cessation trends in patients with bladder cancer presenting to a tertiary referral center. Urology 2012;79:166-71.
- 12. May M, Gilfrich C, Spachmann P, Maurer O, Dombrowski MK, Fritsche HM, et al. What do prostate cancer patients know about smoking?: results of a bicentric questionnaire study (KRAUT study). Urologe A 2016;55:1078-85.

- May M, Maurer O, Lebentrau S, Brookman-May S. Lower use of prostate specific antigen testing by cigarette smokers-Another possible explanation for the unfavorable prostate cancer (PCA) specific prognosis in smokers? Cancer Epidemiol 2017;46:34-5.
- Lortet-Tieulent J, Goding Sauer A, Siegel RL, Miller KD, Islami F, Fedewa SA, et al. State-level cancer mortality attributable to cigarette smoking in the United States. JAMA Intern Med 2016;176:1792-8.
- Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol 2014;66:1054-64.
- Cao S, Gan Y, Dong X, Liu J, Lu Z. Association of quantity and duration of smoking with erectile dysfunction: a dose-response meta-analysis. J Sex Med 2014;11:2376-84.
- Bassett JC, Gore JL, Kwan L, Ritch CR, Barocas DA, Penson DF, et al. Knowledge of the harms of tobacco use among patients with bladder cancer. Cancer 2014;120:3914-22.
- Bjurlin MA, Cohn MR, Freeman VL, Lombardo LM, Hurley SD, Hollowell CM. Ethnicity and smoking status are associated with awareness of smoking related genitourinary diseases. J Urol 2012;188:724-8.
- Westhoff E, Maria de Oliveira-Neumayer J, Aben KK, Vrieling A, Kiemeney LA. Low awareness of risk factors among bladder cancer survivors: new evidence and a literature overview. Eur J Cancer 2016;60:136-45.
- 20. Bassett JC, Gore JL, Chi AC, Kwan L, McCarthy W, Chamie K,

et al. Impact of a bladder cancer diagnosis on smoking behavior. J Clin Oncol 2012;30:1871-8.

- Macleod LC, Dai JC, Holt SK, Bassett JC, Wright JL, Gore JL. Underuse and underreporting of smoking cessation for smokers with a new urologic cancer diagnosis. Urol Oncol 2015;33:504.e1-7.
- 22. Bjurlin MA, Cohn MR, Kim DY, Freeman VL, Lombardo L, Hurley SD, et al. Brief smoking cessation intervention: a prospective trial in the urology setting. J Urol 2013;189:1843-9.
- 23. Lee AS, Ozakinci G, Leung S, Humphris G, Dale H, Hamlet N. Lifestyle change in the cancer setting using 'the teachable moment': protocol for a proof-of-concept pilot in a urology service. Pilot Feasibility Stud 2016;2:65.
- 24. Pietzak EJ, Mucksavage P, Guzzo TJ, Malkowicz SB. Heavy cigarette smoking and aggressive bladder cancer at initial presentation. Urology 2015;86:968-72.
- 25. Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT. Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis 2007;28:1745-51.
- 26. Kwon T, Jeong IG, You D, Han KS, Hong S, Hong B, et al. Obesity and prognosis in muscle-invasive bladder cancer: the continuing controversy. Int J Urol 2014;21:1106-12.
- 27. Bachir BG, Aprikian AG, Izawa JI, Chin JL, Fradet Y, Fairey A, et al. Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration. Urol Oncol 2014;32:441-8.

Supplementary material. Collection of patient related criteria and KRAUT survey with all items (Please consider: the KRAUT study was not specifically developed for UC-patients, but for different urological tumor entities)

KRAUT – Questionnaire A (to be completed	by the physician)
--	-------------------

Cen	ter No.	Patient ID		
Pati	ent and	tumor related questions		
1	Height		Ø	
2	Weight		Ø	
3		f birth (dd/mm/yyyy)	Ø	
4	Date o	f survey (dd/mm/yyyy)	Ø	
5	Date o	f initial diagnosis of tumor disease (dd/mm/yyyy)	Ø	
6	Organ	affected) by urological tumor (multiple options possible)		
	A F	Renal parenchyma		0
	B F	enal pelvis		0
	C ι	Jreter		0
	DU	Jrinary bladder		0
	E F	Prostate		0
	FU	Jrethra		0
	G T	esticles		0
	H F	Penis		0
	I 4	drenal gland		0
7	Histolo	gy of the urological tumor (only one option possible)		
	A A	denocarcinoma		0
	B 5	quamous cell carcinoma		0
	ר C	ransitional cell carcinoma		0
	D S	eminomatous germ cell cancer		0
		Ion-seminomatous germ cell cancer		0
	FC	Clear cell renal cell carcinoma		0
	G N	Ion-clear cell renal cell carcinoma		0
	H N	leuroendocrine carcinoma		0
	1 5	arcoma		0
	JE	Benign tumor		0
		Other histology		0
8		lassification of the tumor according to the 7th edition		
		nswer necessary at each pT, c/pN and c/pM)		
	-	Ta/CIS		0
		T1		0
	-	T2		0
		T3		0
	-	T4		0
		/pN0		0
		/pN+		0
		/pM0		0
		/pM1		0
		Benign tumor		0
	Κρ	T-stage is not applicable to this histology		0

Cent	er No.	Patient ID	
Patie	ent anc	l tumor related questions	
1	Is this	the first time you take part in this survey?	
	Α	No, I have never taken part in this survey	0
	В	Yes, I have already taken part in this survey, but I still do not feel sufficiently informed	0
		about smoking and its relationship with urological tumor occurence and development.	
	С	Yes, I have already taken part in this survey, and I believe I am partially better informed	0
		about smoking and its relationship with urological tumor occurence and development.	
	D	Yes, I have already taken part in this survey, and I believe I am much better informed now	0
		about smoking and its relationship with urological tumor occurence development.	
2	Do yo	ou smoke? (multiple answers possible)	
	Α	I am a non-smoker (neither cigarettes nor tobacco in any other way).	0
	В	I smoke cigarettes.	0
	С	I am a former smoker.	0
	D	I am an occasional smoker (<19 cigarettes per month).	0
	E	I occasionally (not regularly) smoke cigars and/or pipe.	0
	F	I smoke cigars and/or pipe every day.	0
Ansv	ver the	following two questions only if you smoke cigarettes (if not, please continue with question	on
no. 5	5)		
3		ke cigarettes and in total, I have been smoking for xx years (If there was an intermittent per	iod
	of ab:	stinence, please deduct those years)	
	Α	Years Ø	
4	l smo	ke cigarettes and I regularly smoke an average of xxx cigarettes per day.	
	Α	Cigarettes	
		following three questions only if you are a former smoker (if not continue, please continu	ue
with	_	on no. 8)	
5	l am a	a former smoker. I have smoked for xx years.	
	Α	Years Ø	
6		a former smoker. I have smoked on average xxx cigarettes per day.	
	Α	Cigarettes d	
7		e quit smoking xx years ago.	
	Α	Years	
8	Do yo	ou smoke? (multiple answers possible)	
	Α	I am a non-smoker.	0
	В	I have quit smoking due to my tumor disease.	0
	С	I reduced my level of smoking due to my tumor disease.	0
	D	I am currently planning to stop smoking due to my tumor disease.	0
	E	I have changed my smoking habits due to other disease(s) and not because of my tumor	0
		disease.	
	F	I have changed my smoking habits, but this was neither influenced by my tumor disease	0
	F		0
	F G	I have changed my smoking habits, but this was neither influenced by my tumor disease	0

Center	No.	Patient ID			
9 ⊦	lave y	ou ever had an informational conversation about the possibility that the occurrence c	or		
d	development of your tumor might be related to smoking? (multiple options possible, non-				
S	moke	rs should answer as well)			
Δ		lo.	0		
В	3 Y	es, with my family doctor or an internist.	0		
C	С Ү	es, with a resident urologist.	0		
C) Y	es, with a urologist in a hospital.	0		
E	ΞY	es, with a doctor not listed under bullet point B-D.	0		
F	: Y	'es, with other medical staff (e.g. a nurse).	0		
L O ⊢	lave y	ou ever had an informational talk about the possibility that the course (the prognosis)	of		
У	our tu	umor disease might be influenced by smoking? (multiple options possible, non-smoker	ſS		
S	hould	answer as well, too)			
Δ	A N	lo.	0		
В	3 Y	es, with my family doctor or an internist.	0		
C	C Y	es, with a resident urologist.	0		
C) Y	es, with a urologist in hospital.	0		
E	E Y	es, with a doctor not listed under bullet point B-D.	0		
F	: Y	'es, with other medical staff (e.g. a nurse).	0		
11 ⊦	lave y	ou ever been asked by a doctor directly to quit or reduce smoking or not to start smol	king		
(i	(in case you are a non-smoker) due to your current tumor disease?				
Δ	A N	lo.	0		
В	3 Y	′es.	0		
L 2 V	Which	of the following statements apply to you? (two answers necessary, one at A-C, anothe	er		
a	at D-E)				
A	ч т	he occurrence of my current tumor disease is not related to smoking as I have never	0		
	S	moked.			
B		believe that the occurrence of my tumor disease is not related to smoking, although	0		
		am a smoker or former smoker.			
C	C I	am a smoker or former smoker and believe that smoking has/had an influence on	0		
	t	he occurrence of my tumor disease.	Ŭ		
C)	believe that the course of disease (prognosis) of my tumor disease is not influenced	0		
	b	by me due to continuation of smoking or starting to smoke.			
E		believe that the course of disease (prognosis) of my current tumor disease <u>is</u>	0		
	<u>ii</u>	nfluenced by me due to continuation of smoking or starting to smoke			
		nad known about the relationship between the urological tumor disease you are			
d	-	sed with and smoking before you were affected, would you have stopped smoking?			
4		am a non-smoker and I don't/didn't smoke because I would like to prevent tumor	0		
		occurrence and development.			
B		am a non-smoker, but for other reasons than fear of a possible tumor disease.	0		
C		am a smoker and I would have stopped smoking.	0		
C		am a smoker and I would not have stopped smoking.	0		
E		am a former smoke and I have quit smoking for this reason.	0		
F	: 1	am a former smoker, but this was not the reason why I stopped.	0		

2 Please proceed with the next page

Cent	er No.	Patient ID	
Do y	ou thinl	k that the following statements concerning possible relationships between smoking a	and
diffe	rent uro	ological tumor types are correct? Following you find three hypotheses concerning the	е
deve	lopmer	nt of tumors and three hypotheses concerning the course of the tumor disease; only	one
state	ement p	er tumor type is correct. So please tick only one cross per type of tumor and	
deve	lopmer	nt and one per type of tumor and course of disease.	
14	Smoki	ng is one of the main causes for the development of this tumor disease:	
	A l	ung cancer	0
	BE	Bladder cancer	0
	CH	Kidney cancer	0
	DF	Prostate cancer	0
	E F	Penile cancer	0
	F 7	Festicular cancer	0
15	A (non	-proven) relationship between smoking and the development of this tumor disease is	
	being	discussed:	
	A l	ung cancer	0
	B	Bladder cancer	0
	C ł	Kidney cancer	0
	DF	Prostate cancer	0
	E F	Penile cancer	0
	F 1	Festicular cancer	0
16	There	is no relationship between smoking and the development of this tumor disease:	
	A L	ung cancer	0
	B	Bladder cancer	0
	C ł	Kidney cancer	0
	DF	Prostate cancer	0
	E F	Penile cancer	0
	F 1	Testicular cancer	0
17	There	is a relationship between smoking and the course of disease of this tumor:	
	A L	ung cancer	0
	B	Bladder cancer	0
	C ł	Kidney cancer	0
	DF	Prostate cancer	0
	E F	Penile cancer	0
	F 7	Festicular cancer	0

Cent	er No.	Patient ID				
18	A (nor	p-proven) relationship between smoking and the course of disease of this tumor is bein	ng			
	discus	discussed:				
	A I	Lung cancer	0			
	B	Bladder cancer	0			
	C I	Kidney cancer	0			
	D	Prostate cancer	0			
	E í	Penile cancer	0			
	F	Festicular cancer	0			
19	There	is no relationship between smoking and the course of disease of this tumor:				
	A l	Lung cancer	0			
	B	Bladder cancer	0			
	C I	Kidney cancer	0			
	D	Prostate cancer	0			
	E f	Penile cancer	0			
	F	Festicular cancer	0			
20	Do you	u feel well informed about the potential relationship between your tumor disease and				
	smoki	ng (This questions should also be answered by non-smokers, multiple answers possible	e)			
	A I	nformation is not necessary, as there is no relationship between smoking and my	0			
	t	umor disease.				
	B	Yes, I feel well informed. The information provided by media, public education, and	0			
	r	ny physicians is sufficient.	U			
	1 D	No, I don't feel well informed. There is too few information provided by media and	0			
		public education.	U			
	D	No, I don't feel well informed. There is too few information provided by my doctors.	0			
21	Have y	you ever been offered any support by your doctors to help you stop smoking?	_			
	A I	am a non-smoker.	0			
	BI	am a smoker and I have never been offered any of the aids listed below (C-F)	0			
	C	Yes, informational brochures by my family doctor/internist have been provided.	0			
	D	Yes, informational brochures by my urologist have been provided.	0			
		Yes, nicotine replacement therapies and other therapies to change my smoking	0			
		nabits have been suggested or provided by my family doctor/internist.				
		Yes, nicotine replacement therapies and other therapies to change my smoking	0			
		nabits have been suggested or provided by my urologist.				
22	Altogether how much time did your doctors spent to inform you about the possible relationship					
		en smoking and your urological tumor disease?				
	-	have never talked to my doctors about this topic.	0			
		Added together, less than 5 minutes.	0			
		Added together, 5-10 minutes.	0			
		More than 10 minutes.	0			
23		e the conversation took more than 10 minutes (question 22), how many minutes did it				
	last?	Vinutes \mathscr{P}				

Thank you very much for your participation!